|
🐜
|
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
14 auth.
Jan Harder,
G. Ihorst,
Heinemann,
R. Hofheinz,
M. Moehler,
P. Buechler,
G. Kloeppel,
Christoph Röcken,
M. Bitzer,
S. Boeck,
...
Esther Endlicher,
Anke C. Reinacher-Schick,
C. Schmoor,
Michael Geissler
|
7 |
2012 |
7
🐜
|
|
🐜
|
mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109).
11 auth.
Michael Geissler,
T. Klingler,
J. Riera-Knorrenschield,
A. Tannapfel,
Thomas Seufferlein,
S. Held,
...
A. Florschütz,
S. Kanzler,
V. Heinemann,
Anke C. Reinacher-Schick,
Uwe M. Martens
|
5 |
2017 |
5
🐜
|
|
🐬
|
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
Christiane Schneider-Gold,
Anke C. Reinacher-Schick,
G. Ellrichmann,
Ralf Gold
|
5 |
2017 |
5
🐬
|
|
🐜
|
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
18 auth.
M. Haas,
J. Siveke,
M. Schenk,
M. M. Lerch,
Karel Caca,
J. Freiberg-Richter,
L. F. V. Weikersthal,
Frank Kullmann,
Anke C. Reinacher-Schick,
Miriam Fuchs,
...
S. Kanzler,
Volker Kunzmann,
T. Ettrich,
Stephan Kruger,
C. Westphalen,
S. Held,
Volker Heinemann,
S. Boeck
|
5 |
2018 |
5
🐜
|
|
🐜
|
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
17 auth.
L. Kessler,
N. Hirmas,
K. Pabst,
R. Hamacher,
J. Ferdinandus,
B. Schaarschmidt,
A. Milošević,
Michael Nader,
L. Umutlu,
W. Uhl,
...
Anke C. Reinacher-Schick,
C. Lugnier,
David Witte,
Marco Niedergethmann,
Ken Herrmann,
W. Fendler,
Jens T Siveke
|
3 |
2023 |
3
🐜
|
|
🐜
|
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).
12 auth.
Michael Geissler,
J. Riera-Knorrenschild,
A. Tannapfel,
J. Greeve,
A. Florschütz,
S. Wessendorf,
...
Thomas Seufferlein,
S. Kanzler,
S. Held,
Volker Heinemann,
Anke C. Reinacher-Schick,
Uwe M. Martens
|
2 |
2018 |
2
🐜
|
|
🐜
|
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
20 auth.
K. Dorman,
S. Boeck,
Karel Caca,
Maximilian Reichert,
T. Ettrich,
H. Oettle,
Oliver Waidmann,
D. Modest,
Lothar Müller,
Patrick Michl,
...
S. Kanzler,
Daniel Pink,
Anke C. Reinacher-Schick,
Michael Geissler,
Henning Pelz,
Volker Kunzmann,
S. Held,
T. Schichtl,
Volker Heinemann,
Frank Kullmann
|
1 |
2024 |
1
🐜
|
|
🐜
|
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
20 auth.
L. Weiss,
Volker Heinemann,
L. E. Fischer,
F. Gieseler,
T. Hoehler,
J. Mayerle,
D. Quietzsch,
Anke C. Reinacher-Schick,
M. Schenk,
G. Seipelt,
...
J. Siveke,
M. Stahl,
U. Vehling‐Kaiser,
D. Waldschmidt,
K. Dorman,
Danmei Zhang,
C. Westphalen,
Michael von Bergwelt-Baildon,
S. Boeck,
M. Haas
|
0 |
2023 |
0
🐜
|
